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Obstructive sleep apnea (OSA) is charac-
terised by repetitive episodes of upper airway oc-
clusion during sleep. Nasal inflammation, uvula
mucosal congestion, airway inflammation and air-
way hyperreactivity have been shown to be associ-
ated with OSA [1, 2, 3]. These alterations, togeth-
er with a described low grade systemic inflamma-
tion, may play a role in the clinical manifestation
and in the complications of OSA patients. In addi-
tion, airway inflammation may contribute to the
pathogenesis of the disease by further decreasing
airway caliber.
Airway inflammation in OSA
Several studies have demonstrated the pres-
ence of mucosal oedema and structural mucosal
changes in the upper airway of patients with OSA.
Rubinstein et al [1] have described the presence of
nasal inflammation in OSA and have suggested
that this abnormality may further aggravate the up-
per airway obstruction. In this study, a local mu-
cosal increase in both polymorphonuclear leuko-
cytes and flogosis mediators such as bradykinin
and vasoactive intestinal peptide (VIP) were
shown. Sekosan et al [2] and Zakkar et al [4] have
shown inflammation in the soft palate of OSA pa-
tients, in the form of increased thickness of uvula
mucosa, interstitial oedema and higher number of
leukocytes in the lamina propria of these districts.
The authors have suggested that upper airway soft
tissues inflammation plays a critical role in the
pathogenesis of upper airway narrowing during
sleep in OSA patients.
Several studies have demonstrated the pres-
ence of airway inflammation mediators in OSA. A
significant decrease of neutral endopeptidase, a
mediator that inactivates pro-inflammatory pep-
tides eliciting interstitial edema, has been de-
scribed [4]; on the other hand, increased local lev-
els of inflammatory mediators have been demon-
strated in obese OSA patients, suggesting the de-
velopment of inflammation in the airways during
sleep. The non-invasive evaluation in the exhaled
air of OSA patients, of airway inflammation and
oxidative stress markers as pentane and exhaled
nitric oxide (eNO) performed by Olopade et al [5],
have suggested the development of airway inflam-
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Obstructive sleep apnea (OSA) is characterised by
repetitive episodes of upper airway occlusion during
sleep. OSA has been shown to be associated with a vari-
able degree of nasal inflammation, uvula mucosal con-
gestion and airway hyperreactivity. The upper airway
inflammation, whose clinical importance is uncertain, is
characterised by leukocytes infiltration and interstitial
oedema. In addition, recent data has shown the presence
of neutrophilic inflammation in the lower airways. The
current opinion is that airway inflammation is caused by
the local, repeated mechanical trauma related to the in-
termittent airway occlusion typical of the disease. Anoth-
er potential mechanism involves the intermittent noctur-
nal hypoxemia that through the phenomenon of the is-
chemia-reperfusion injury may induce the production of
oxygen free radicals and therefore cause local and sys-
temic inflammation. Finally, a state of low-grade sys-
temic inflammation may be related to obesity per se with
the pro-inflammatory mediators synthesised in the vis-
ceral adipose cells. Several authors stress the role of cir-
culating and local inflammatory mediators, such as pro-
inflammatory cytokines, exhaled nitric oxide, pentane
and 8-isoprostane as the determinants of inflammation in
OSA.
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mation during sleep in this type of patients. Re-
cently, Carpagnano et al [6] measured high levels
of two markers of inflammation and oxidative
stress, IL-6 and 8-isoprostane, in the exhaled
breath condensate of obese patients with OSA.
A recent study [7] demonstrated the presence
of lower airway inflammation in OSA using the
analysis of induced sputum, a valid and widely
used technique to investigate the bronchial inflam-
matory profile, characterised by a variable degree
of neutrophilic airway inflammation. In this study,
none of the patients were smokers, nor did they
have a history of acute or chronic respiratory dis-
ease. The clinical role of this abnormality is cur-
rently under investigation.
Potential mechanisms of inflammation in OSA
It is not completely known why there is airway
inflammation in OSA. There are several possible
explanations for the presence of inflammation in
the airways of OSA patients. The upper airways
and in particular the nasal inflammation are be-
lieved to be the consequence of the mechanical
stress associated to the obstruction of the air pas-
sage, typical of the disease. The repeated mechan-
ical trauma on the airways related to snoring, to-
gether with the airway vibration and the forceful
suction collapse during apnoeas, likely triggers an
inflammatory response locally [8, 9]. Regarding
the lower airways, the mechanical stress exerted
on the mucosa of the respiratory system by the
snoring and the apneas, may also be responsible
for bronchial inflammation. In fact, a strong inspi-
ratory effort against a closed airway passage cre-
ates a negative pressure which is transmitted to all
the respiratory system. The “pressure trauma” may
not be the exclusive mechanism involved. A link
between airway inflammation and sleep apnea is
present in asthma, an inflammatory disease often
associated to OSA. Snoring and apnoea, in fact,
occur in patients with bronchial asthma more fre-
quently in respect to the general population [10],
probably because of the occurrence of rhinitis and
nasal poliposis that induce increased nasal resis-
tance and negative pressure in the upper airways
during inspiration. The airway collapse and the air
turbulence may predispose to the worsening of the
bronchoconstriction and to the appearance of OSA
[11]. Furthermore, nocturnal hypoxemia itself can
induce reflex bronchoconstriction through stimu-
lation of carotid bodies [12]. In addition upper air-
way reactivity measured using transient reflex la-
ryngeal closure, is increased in OSA patients. This
effect is likely to be secondary to the inflammation
of the epithelium lining of the upper airway fol-
lowing the repeated airway obstruction, allowing
the passage of inhaled irritant to the sub-epithelial
receptors [13].
OSAS may induce lung function abnormali-
ties. In so far as intermittent upper airway obstruc-
tion is the most important feature of OSA, Bijaoui
et al [14] in a recent study tested the hypothesis
that the repetitive apnoea episodes are accompa-
nied by modifications in the respiratory system.
Indeed, upper airway obstruction in OSA predis-
pose to alterations in lung and airway functions.
Bijaoui proposes that the observed increase in lung
elastance and lung resistance, during obstructed
breathing, may lead to nocturnal transient abnor-
malities in the recruitment of lung units and in the
gas exchanging capacity of the lungs.
A state of low-grade systemic inflammation
seems to be present in obese adults with OSA, and
to some extent in obese adults without OSAS. Air-
way inflammation may be, at least in part, the
epiphenomena of this systemic inflammation.
Entzian et al [15] suggested the critical role of cir-
culating cytokines in the pathogenesis of OSA;
Vgontzas et al [16, 17] found that the concentra-
tions of circulating Il-6 and TNF-α were higher in
obese subjects affected by sleep apnoea compared
to non apnoeic obese subjects; however, the high
levels of pro-inflammatory cytokines correlated
with nocturnal hypoxemia, diurnal hypersomnia
and daytime fatigue measured in healthy subjects
with poor refreshing sleep. Elevated levels of in-
flammatory markers, IL-6, TNF-α, and CRP have
been demonstrated in OSA patients but not in con-
trol obese subjects without OSA. Moreover, CRP
levels were correlated with the severity of OSA,
BMI and nocturnal hypoxemia [16, 18, 19]. These
findings, taken together, suggest the presence of
systemic inflammation in OSA subject, that may
also be involved in the elevated prevalence of car-
diovascular and coronary artery diseases described
respect to general population. Apneas and arousal
events, induce an increase of heart rate and blood
pressure values related to both a raise in gradient
intrathoracic pressure, to nocturnal hypoxia and to
inflammatory response [20, 21, 22].
Some authors have hypothesised the impor-
tance of the body fat distribution in the obese pa-
tients, particularly emphasising the importance of
the amount of omental adipose tissue in the syn-
thesis of systemic cytokines, a condition, however,
not necessary correlated with sleep apnoea [23].
Recently, some authors have supported the
role, as a pro-inflammatory mechanism in OSA
patients, of the intermittent nocturnal hypoxemia
and the relative ischemia-reperfusion injury. Simi-
lar to the ischemia/reperfusion injury seen in coro-
nary artery disease and stroke, sleep apnea is ac-
companied by cyclical alterations of arterial oxy-
gen saturation, with oxygen desaturations in re-
sponse to apneas followed by resumption of oxy-
gen saturation during hyperventilation. The conse-
quent excessive oxygen free radicals production
(“oxidative stress”) would result in local and sys-
temic inflammation [8, 16, 24], likely contributing
to the development of cardiovascular disease [25].
Indeed, reactive plasmatic oxygen species (ROS)
are associated with OSA with activation of inflam-
matory cells [26] and increased cytokines levels.
The inflammatory cells activated by systemic me-
diators such as TNF-α, IL-1, Il-6 and IFN-γ may
express adhesion molecules which in turn may re-
sult in increased endothelial cells/leucocytes inter-
actions that may trigger the atherogenic processes
[27, 28]. No conclusive data exists on the potential
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role of local airway production of ROS on airway
inflammation, their influence on inflammatory ex-
haled markers, and bronchial inflammatory cells
pattern. However, an involvement in the genesis of
airway inflammation is likely.
At the moment, no data demonstrates a clear
correlation between airway inflammation markers
and obesity in OSA patients. Recently Carpagnano
et al [6] measuring the levels of markers of airway
inflammation and oxidative stress in the exhaled
breath condensate in OSA, found a significant pos-
itive correlation between those markers and neck
circumference, or the severity of sleep apnea.
A further mechanism by which airway inflam-
mation may be present in OSA is through the pres-
ence of asthma, that is prevalent in obesity [29].
Obesity, in fact, by altering the chest wall mechan-
ics, determines a shift of the elastic equilibrium be-
tween lung and chest wall recoil towards a lower
functional residual capacity. In so far as there is
mechanical interdependence between the lung
parenchyma and the intraparenchymal airways, a
lower lung volume decreases the tethering of the
lung parenchyma on the airways, diminishing the
mechanical load opposing the airway narrowing
and therefore facilitating airway hyperresponsive-
ness and asthma (30).
CPAP and airway inflammation in OSA
Nasal continuous positive airway pressure
(nCPAP) is a common treatment for OSA. nCPAP
improves diurnal and nocturnal symptoms, in ad-
dition to the snoring and the often co-existing
bronchial asthma. Indeed, nCPAP, by reducing air-
way obstruction and the desaturation events, may
decrease the neural reflex of bronchoconstriction
[31, 32]. The effectiveness of nCPAP in reversing
airway inflammation and airway hyperreactivity is
less compelling. In the study of Nandwani et al
[33], a 3-month treatment of OSA patients with
nCPAP reversed upper airway reactivity likely
secondary to the inflammation of the epithelium
lining of the airways. Wenzel [34], in his study,
supports the concept that in OSA patients with
bronchial hyperreactivity the benefits of CPAP ex-
cel the potential adverse effects. On the contrary,
when bronchial provocation tests are performed
before and after two days of treatment with nC-
PAP, a worsening of the bronchial hyperreactivity
has been shown [35]. Nonetheless no conclusive
data is available on this regard. CPAP may repre-
sent, because of the high mean airway pressure, a
mechanical stimulus on the airways theoretically
able to determine an inflammatory response.
Conclusion
In conclusion, patients affected by OSA, dis-
play upper and lower airway inflammation. Air-
way inflammation may be the result of the me-
chanical stress on the mucosa caused by intermit-
tent airway obstruction, the consequence of noc-
turnal hypoxia, or a systemic inflammation. Fur-
ther studies are necessary in order to assess the
clinical importance of inflammation in OSA, and
the effectiveness of the anti-inflammatory therapy
on reducing the OSA-induced airway inflamma-
tion and in modifying the natural history of the dis-
ease. It is possible that in addition to CPAP thera-
py, surgery and weight reduction, patients affected
by OSA may benefit also from treatment aimed at
reducing local and systemic inflammation.
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